Ingenuity is at the center of pharmacy care

We publish the IngenioRx Drug and Biologic Pipeline Update each quarter to keep our audiences informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest. Open the attachment to learn about:

1. A new topical therapy for psoriasis, a first-in-class therapy for Niemann-Pick disease type B, and a new dual mechanism of action agent for type 2 diabetes.
   
   
2. Other select significant product approvals, including biosimilars, expected in 2022.
   
   
3. Future indications being pursued for Dupixent® (dupilumab), a biologic used to treat asthma, atopic dermatitis, and nasal polyps.
   
   
4. Approvals that originally came to market through the accelerated approval pathway and have been withdrawn by the FDA.
   
   
5. The non-alcoholic steatohepatitis (NASH) pipeline and uptake of the human papillomavirus (HPV) vaccine.

Healthcare is a team effort. It is common for a person to see many doctors, especially when they are sick or manage a disease that affects more than one part of their body. To help our members get the best care, IngenioRx is investing in digital solutions. Our innovative tools can strengthen connections between members, doctors, and pharmacists at key points in the healthcare journey, such as:

• Visits to doctors and pharmacies
• Communication between pharmacists and IngenioRx
• Meaningful data collection, to create personalized experiences

CLOSING GAPS IN CARE

The growing presence of technology in our lives has not perfected access to healthcare; people still experience gaps. Communication between doctors is not standardized, and they may use different electronic medical record (EMR) systems. Once a drug is prescribed, there can be many reasons why a member may miss doses or refills.

With reliable access to clear information, doctors can better address barriers to care. IngenioRx encourages bidirectional information that can be shared between a member, doctor, pharmacy benefit manager, and health plan. Our EMR-enhancing solutions allow doctors to view pharmacy insights in the exam room. With bidirectional capability, doctors can view care gaps in their EMR system. They can do real-time pharmacy benefit checks to make sure the drug they want to prescribe is available, affordable, and effective for the member. If a drug is not the best fit, IngenioRx may recommend another option, such as a generic that works equally well. Doctors can send e-prescriptions and, in many cases, get instant electronic preapproval. This all happens before a member leaves the doctor’s office.

Once a prescription is filled, member-facing digital tools can help make sure the member takes their drug. Members who qualify may log in to a member website or app to set reminders, price drugs, or ask to change where and when they refill prescriptions. Certain members can also chat live with IngenioRx pharmacy care specialists about specialty drugs, home delivery, or general pharmacy issues.¹

For members are less comfortable with technology, machine learning and artificial intelligence can still improve experiences. Using lab, medical, and pharmacy claims data, we can identify when members’ behaviors may put their health at risk. Using each member’s communication preference, IngenioRx can reach out when they don’t take their medicine, miss refills, or overuse prescription drugs.

REDUCING DRUG COSTS AND UTILIZATION

As we expand our digital efforts, we’ve conducted multiple studies that have shown our efforts work.

IngenioRx case study 1:²

• Large, value-based care company started a program to lower use of high-cost drugs while maintaining health outcomes.
  • Engaged IngenioRx pharmacists and used our digital tools.
  • 33% decrease in high-cost drug use.

IngenioRx case study 2:³

• Large, multispecialty health system in the Los Angeles area started a program to lower use of high-cost drugs.
  • Provided materials to high-volume doctors to educate them on other options to highlight value and drive conversations.
  • 33% decrease in high-cost drug use, 42% decrease in drug costs.

IngenioRx 2020 medication review:⁴

• 34.9% care gaps closed.
• 40.5% members more compliant with medications (any level of improvement).
• $0.68 per member per month (PMPM) pharmacy savings.
• $2.11 PMPM medical costs offset.

IngenioRx uses meaningful data to create personalized pharmacy care. While terms like “machine learning” and “artificial intelligence” can sound lofty, our goal is simple: using our ingenuity to improve the health of humanity. When members, doctors, pharmacists, and health plans can easily work together, our goal feels closer than ever.

1. Individual member portal and app features are subject to availability and may change over time.
   
   
2. IngenioRx case study, Nevada, 2020.
   
   
3. IngenioRx case study, California, 2020–2021.
   
   
4. IngenioRx 2020 clinical and cost-of-care programs data for Enterprise and Commercial exchange business.

IngenioRx’s DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities, formulations, and indications.